TG Therapeutics (NASDAQ:TGTX) Stock Price Down 6.3%

TG Therapeutics Inc (NASDAQ:TGTX)’s stock price was down 6.3% during trading on Thursday . The stock traded as low as $7.63 and last traded at $7.68, approximately 1,758,215 shares traded hands during mid-day trading. An increase of 8% from the average daily volume of 1,624,737 shares. The stock had previously closed at $8.20.

Several brokerages have recently commented on TGTX. HC Wainwright reaffirmed a “buy” rating and issued a $20.00 target price on shares of TG Therapeutics in a research report on Tuesday, November 12th. B. Riley began coverage on TG Therapeutics in a research report on Wednesday, November 27th. They set a “buy” rating and a $12.00 price target on the stock. Zacks Investment Research downgraded TG Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, November 15th. BidaskClub upgraded TG Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, November 7th. Finally, ValuEngine lowered TG Therapeutics from a “buy” rating to a “hold” rating in a research report on Monday, October 21st. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. TG Therapeutics has a consensus rating of “Buy” and an average price target of $12.95.

The company has a debt-to-equity ratio of 2.77, a quick ratio of 1.00 and a current ratio of 1.00. The business’s 50 day simple moving average is $7.14 and its 200-day simple moving average is $6.93.

TG Therapeutics (NASDAQ:TGTX) last announced its quarterly earnings data on Tuesday, November 12th. The biopharmaceutical company reported ($0.69) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.36) by ($0.33). TG Therapeutics had a negative return on equity of 2,411.79% and a negative net margin of 123,130.93%. The firm had revenue of $0.04 million for the quarter, compared to analysts’ expectations of $0.04 million. Equities research analysts expect that TG Therapeutics Inc will post -1.96 earnings per share for the current fiscal year.

A number of large investors have recently added to or reduced their stakes in the stock. Aperio Group LLC bought a new position in TG Therapeutics during the second quarter valued at approximately $32,000. Virtu Financial LLC bought a new stake in TG Therapeutics in the third quarter worth approximately $69,000. Bank of Montreal Can raised its holdings in shares of TG Therapeutics by 1,119.0% during the 2nd quarter. Bank of Montreal Can now owns 8,143 shares of the biopharmaceutical company’s stock valued at $70,000 after purchasing an additional 7,475 shares in the last quarter. Centaurus Financial Inc. raised its holdings in shares of TG Therapeutics by 12,400.0% during the 2nd quarter. Centaurus Financial Inc. now owns 10,000 shares of the biopharmaceutical company’s stock valued at $87,000 after purchasing an additional 9,920 shares in the last quarter. Finally, Tower Research Capital LLC TRC bought a new position in shares of TG Therapeutics during the 2nd quarter valued at $98,000. Hedge funds and other institutional investors own 48.63% of the company’s stock.

About TG Therapeutics (NASDAQ:TGTX)

TG Therapeutics, Inc, a biopharmaceutical company, engages in developing and delivering medicines for patients with chronic lymphocytic leukemia (CLL), non-Hodgkin's Lymphoma (NHL), and Multiple Sclerosis (MS). It develops a robust B-cell directed research and development platform for identification of key B-cell pathways of interest and rapid clinical testing.

Read More: What is a bull market?

Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.